← All trials
NCT04214990
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2020
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2028
- First posted
- —
- Last posted
- —
- Enrollment
- 1700
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Cancer Center, KoreaLead sponsor
- National Cancer Center, KoreaReponsible party - principal investigator
- National Cancer Center, KoreaStudy director
- Kosin UniversityCollaborator
- Seoul National UniversityCollaborator
- Seoul National UniversityCollaborator
- University of UlsanCollaborator
- Chung-Ang UniversityCollaborator
- Catholic University of KoreaCollaborator
- Kyungpook UniversityCollaborator
- Hallym UniversityCollaborator
- Chonnam National UniversityCollaborator
- Pusan National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.